• 1
    American Cancer Society. Cancer Facts and Figures 2004. Atlanta, GA: American Cancer Society, 2004.
  • 2
    Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 103137.
  • 3
    Ranson M, Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther 2004; 29: 95103.
  • 4
    Chu E. Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer. Clin Colorectal Cancer 2004; 3: 205.
  • 5
    Hurwitz H, Fehrenbacler L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 233542.
  • 6
    Marton LJ, Pegg AE. Bevacizumab plus irinotecan, fluorouacil, and leucovorin for metastatic colorectal cancer. Annu Rev Pharmacol Toxicol 1995; 27: 42542.
  • 7
    Schechter PJ, Barlow JLR, Sjoerdsma A. Clinical aspects of inhibition of ornithine decarboxylase with emphasis on therapeutic trials of Eflornithine (DFMO) in cancer and protozoan diseases. In: McCannPP, PeggAE, SjoerdsmaA, eds. Inhibition of polymine metabolism biological significances and basis for new therapies. Orlando: Academic Press, 1987; 34563.
  • 8
    Fischer SM, Lee M, Lubet RA. Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice. Carcinogenesis 2001; 22: 838.
  • 9
    Chen YL, Hu J, Boorman D, Klein-Szanto AJ, O'Brien TG. Therapy of murine squamous cell carcinomas with 2-difluoromethylornithine. J Carcinog 2004; 3: 1020.
  • 10
    Byers TL, Pegg AE. Properties and physiological function of the polyamine transport system. Am J Physiol 1989; 256: C160C167.
  • 11
    Weeks RS, Vanderwerf SM, Carlson CL, Burns MR, O'Day CL, Cai F, Devens BH, Webb HK. Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO. Exp Cell Res 2000; 26: 193302.
  • 12
    Burns MR, Carlson CL, Vanderwerf SM, Ziemer JR, Weeks RS, Cai F, Webb HK, Graminski GF. Amino acid/spermine conjugates: polyamine amides as potent spermidine uptake inhibitors. J Med Chem 2001; 44: 363244.
  • 13
    Megosh L, Gilmour SK, Rosson D, Soler AP, Blessing M, Sawicki JA, O'Brien TG. Increased skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res 1995; 55: 42059.
  • 14
    Koza RA, Megosh LC, Palmieri M, O'Brien TG. Constitutively elevated levels of ornithine and polyamines in mouse epidermal papillomas. Carcinogenesis 1991; 12: 161925.
  • 15
    Kabra PM, Lee HK, Lubich WP, Marton LJ. Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography: improved separation systems for polyamines in cerebrospinal fluid, urine and tissue. J Chromatogr 1986; 380: 1932.
  • 16
    Metcalf R, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP. Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C. by substrate and product analogues. J Am Chem Soc 1978; 100: 25513.
  • 17
    O'Shaughnessy JA, Demers LM, Jones SE, Arseneau J, Khandelwal P, George T, Gersh R, Mauger D, Manni A. α-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res 1999; 5: 343844.
  • 18
    Levin VA, Hess KR, Choncair A, Flynn PJ, Jacekle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Irtech S, Gleason MJ, Kim HW, et al. Phase III randomized study of postradiotherapy chemotherapy with combination α-difluoromethylormithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003; 9: 98190.
  • 19
    Peralta Soler A, Gilliard G, Megosh L, George K, O'Brien TG. Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res 1998; 58: 16549.
  • 20
    Fong LYY, Nguyen VT, Pegg AE, Maggee PN. α-Difluoromethylornithine induction of apoptosis: a mechanism which reverses pre-established cell proliferation and cancer initiation in esophageal carcinogenesis in zinc-deficient rats. Cancer Epidemiol Biomarkers Prev 2001; 10: 1919.
  • 21
    Li H, Schut HAJ, Conran P, Kramer PM, Lubet RA, Steele VE, Hawk EE, Kelloff GJ, Pereira MA. Prevention by aspirin and its combination with α-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 1999; 20: 42530.
  • 22
    Takahashi Y, Mai M, Nishioka K. α-Difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibitiion of tumor growth and metastasis in a human gastric cancer mode. Int J Cancer 2000; 85: 2437.
  • 23
    Luk GD, Abeloff MD, Griffin CA, Baylin SB. Successful treatment with DL-α-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice. Cancer Res 1983; 43: 423943.
  • 24
    Upp JR,Jr, Beauchamp RD, Townsend CM,Jr, Barranco SC, Singh P, Rajaraman S, James E, Thompson JC. Inhibition of human gastric adenocarcinoma xenograft growth in nude mice by α-difluoromethylornithine. Cancer Res 1988; 48: 32659.